EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Margetuximab for HER2-Positive Breast Cancer

Another possible reason for increased infusion-related reactions may be related to its mechanism of action with an enhanced immune response. Are there any major drug interactions with margetuximab that clinicians should be aware of? A: The important drug interactions are with other cardiotoxic drugs...

Full description

Saved in:
Bibliographic Details
Published inOncology (Williston Park, N.Y.) Vol. 35; no. 9; p. 573
Main Author Cuellar, Sandra
Format Journal Article
LanguageEnglish
Published Monmouth Junction Intellisphere, LLC 01.09.2021
MultiMedia Healthcare Inc
Subjects
Asymptomatic
Breast cancer
Cancer
Cancer therapies
Cardiotoxicity
Chemotherapy
Clinical trials
Drug dosages
Drug interactions
Ejection fraction
Metastasis
Monoclonal antibodies
Patients
Online AccessGet full text

Cover

More Information
Summary:Another possible reason for increased infusion-related reactions may be related to its mechanism of action with an enhanced immune response. Are there any major drug interactions with margetuximab that clinicians should be aware of? A: The important drug interactions are with other cardiotoxic drugs. In the breast cancer world, the primary drug interaction here would be doxorubicin.
ISSN:0890-9091